STAR治疗会减少并发症和死亡与高风险心脏节奏患者的死亡率。 STAR therapy cuts complications and deaths vs. ablation in high-risk heart rhythm patients.

一项新的研究发现,与重复导管切除相比,立体心律失常的放射治疗 (STAR) 在重症,耐药的腹腔动脉动脉症的高危患者中显著减少了严重并发症和死亡. A new study finds stereotactic arrhythmia radiation therapy (STAR) significantly reduces serious complications and deaths compared to repeat catheter ablation in high-risk patients with severe, medication-resistant ventricular tachycardia. 在43名病人中,只有9%的接受放射治疗的病人在一年内因不利事件住院治疗,38%的病人在通缩组内住院治疗,有4人死亡在通缩组内,没有一人在辐射组内。 Among 43 patients, only 9% treated with radiation had hospitalizations due to adverse events within a year, versus 38% in the ablation group, with four deaths in the ablation group and none in the radiation group. 辐射后(中度为10个月)比烧死后(中度为6天)发生并发症的时间要晚得多。 Complications arose much later after radiation (median 10 months) than after ablation (median 6 days). 辐射治疗是一种非侵入性、单片治疗,目标是没有麻醉或导管而导致心律不齐的疤痕组织,为医疗脆弱病人提供了更安全的替代方案。 Radiation therapy, a noninvasive, single-session treatment, targets scar tissue driving arrhythmias without anesthesia or catheters, offering a safer alternative for medically fragile patients. 研究结果将提交给美国辐射肿瘤学学会会议,并发表在《国际辐射肿瘤学杂志》上。 Results will be presented at the American Society for Radiation Oncology meeting and published in the International Journal of Radiation Oncology • Biology • Physics.